🚨 NATALEE: Kisqali® + ET reduced death risk by ~20% in high-risk HR+/HER2− early breast cancer (OS HR 0.809). 6-year iDFS benefit: 5.3%.

返回会议原文

返回会议

ONCOassist® | The go-to oncology app· @ONCOassist · X·2026-10-24 23:00· 14 小时前评分70

NATALEE

正文 · 机器翻译

🚨 NATALEE：Kisqali® + ET 将高危 HR+/HER2− 早期乳腺癌患者的死亡风险降低约 20%（OS HR 0.809）。6 年 iDFS 获益：5.3%。

🔗 https://campaign.oncoassist.com/XesmoCon2

📍 参加 ESMO Congress 2026？前往 ONCOassist 的 1091 号展位参观。

#BreastCancer #ESMO26

30 浏览 · 0 赞 · 0 转发 · 0 回复

会议摘要

LBA25按 Proffered paper 1: Breast cancer, early and advanced stage 对上

Adjuvant ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 6-y overall survival (OS) and efficacy outcomes

https://esmocongress.esmo.org

来源：ONCOassist® | The go-to oncology app · x.com